Latest Posts

30

May 24

Partex and Singapore’s Experimental Drug Development Centre collaborate to bring forward an innovative approach for early drug discovery and development

featured, Press release 2024
Frankfurt, Germany, 3rd June 2024, 9am CET Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled...
Read More

22

Apr 24

Partex Partners with Lupin to Revolutionize Drug Discovery through AI-Driven Asset Search and Evaluation

featured, Press release 2024
Frankfurt, Germany, 23 April 2024 – Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled to...
Read More

Innoplexus wins Horizon Interactive Gold Award for Curia App

Read More
Try Ontosight® For Free

Catana Capital: New collaboration with Life Science AI pioneer Innoplexus

Catana Capital partners with a leading provider of AI solutions in the Life Science sector

Frankfurt am Main, December 16, 2019: As a pioneer in the application of Big Data and AI for quantitative asset management, Catana Capital is always open to collaborate with other innovators in the space in order to develop new innovative investment strategies. After a successful first year of the Data Intelligence Fund and the recent launch of overlay strategies for institutional investors, Catana Capital has now partnered with Innoplexus, a leading provider of artificial intelligence solutions in the Life Science sector.

Innoplexus has proven to provide deep insights into the Life Sciences data universe and especially the assessment of outcomes of clinical trials, which, combined with Catana Capital“s know how and experience in quantitative asset management, will form the basis for a successful joint venture. Innoplexus“ proprietary use of artificial intelligence and machine learning fits perfectly into Catana Capital“s strategy to further scale its revolutionary new investment strategy based on independent trading signals in the area of European pharmaceutical equities, where both companies will work together on an exclusive basis.

Catana Capital“s innovative Data Intelligence Fund (ISIN: DE000A2H9A76) has met all expectations since its launch and the additional approach into the pharma sector is a solid diversification within the fund which will further contribute to its success.

Catana Capital GmbH is a financial services institution licensed in compliance with Section 32 of the German Banking Act (KWG) and domiciled in Frankfurt am Main. The FinTech was founded in August 2015 and manages the Data Intelligence Fund, a public fund based entirely on big data and artificial intelligence. Catana Capital sees itself as a pioneer in the development of new approaches to asset management and offers innovative investment products for private investors and institutional clients.

Further information can be found at https://catanacapital.com/

Originally published on Press Network.

Featured News

Strategic partnership announcement: Innoplexus holding company Partex NV is pleased to announce a one-of-its-kind collaboration with Anavex Life science corp. for Artificial Intelligence (AI) enabled drug development and healthcare sales marketing
on June 27, 2023

Strategic partnership announcement: Innoplexus holding company Partex NV is pleased

Exciting News! Anavex Life Sciences and Partex NV Announce Strategic Partnership to Enhance Patient Experience. Anavex Life Sciences Corp. and Partex NV N.V. Group are pleased to announce…

Read More